Central Serous Chorioretinopathy Following Intravitreal Dexamethasone Implant

Published on Aug 1, 2019in Korean Journal of Ophthalmology
· DOI :10.3341/KJO.2018.0115
Gwang Myeong Noh2
Estimated H-index: 2
(Kosin University),
Ki Yup Nam9
Estimated H-index: 9
(Kosin University)
+ 1 AuthorsSang Joon Lee12
Estimated H-index: 12
(Kosin University)
📖 Papers frequently viewed together
2 Citations
3 Citations
#1Michael SingerH-Index: 15
#2Pravin U. DugelH-Index: 51
Last. John MaltmanH-Index: 3
view all 5 authors...
BACKGROUND AND OBJECTIVE: Dexamethasone intravitreal implant (DEX) (Ozurdex; Allergan plc, Dublin, Ireland) is approved for the treatment of diabetic macular edema (DME). This study assessed the real-world effectiveness, safety, and reinjection interval of DEX in adult patients with DME. PATIENTS AND METHODS: This was a phase 4, prospective, multicenter (18 U.S. sites), observational study. RESULTS: The study population comprised 177 patients (180 eyes; 93.8% previously treated). Baseline mean b...
14 CitationsSource
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has not been reported in the literature before.
2 CitationsSource
#1Ilias Georgalas (UoA: National and Kapodistrian University of Athens)H-Index: 23
#2Petros Petrou (UoA: National and Kapodistrian University of Athens)H-Index: 13
Last. Ioannis TservakisH-Index: 5
view all 5 authors...
Central serous chorioretinopathy is the fourth most frequent retinal disorder after age‐related macular degeneration, diabetic retinopathy and retinal vein occlusion and is characterised by an idio...
3 CitationsSource
#1Jeong Mo Han (Seoul National University Hospital)H-Index: 8
#2Jeong-Min Hwang (Seoul National University Bundang Hospital)H-Index: 18
Last. Se Joon Woo (Seoul National University Bundang Hospital)H-Index: 39
view all 5 authors...
PURPOSE: To characterize the effects of corticosteroids on choroidal thickness, we measured the choroid thickness in patients treated systemically with a high-dose corticosteroid. METHODS: A prospective, pilot study was conducted on 20 patients who required high-dose corticosteroid pulse therapy (>500 mg/d). Choroidal thickness was measured at baseline, 1 day, 1 week, and 1 month after corticosteroid administration. Blood pressure was measured four times a day for the first 5 days of steroid tre...
27 CitationsSource
#1Joan-En Chang-Lin (Allergan)H-Index: 4
#2Mayssa Attar (Allergan)H-Index: 10
Last. Devin F. Welty (Allergan)H-Index: 12
view all 7 authors...
PURPOSE: To determine the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.). METHODS: Thirty-four male monkeys (Macaca fascicularis) received bilateral 0.7-mg DEX implants. Blood, vitreous humor, and retina samples were collected at predetermined intervals up to 270 days after administration. DEX was quantified by liquid chromatography-tandem mass spectrometry, and cytochrome P450 3A8 (CYP3A8) gene expression was analy...
353 CitationsSource
Cited By2
#1Richard F. SpaideH-Index: 105
#2Chui Ming Gemmy Cheung (SingHealth)H-Index: 37
Last. Peter MalocaH-Index: 9
view all 14 authors...
In central serous chorioretinopathy (CSC), the macula is detached because of fluid leakage at the level of the retinal pigment epithelium. The fluid appears to originate from choroidal vascular hyperpermeability, but the etiology for the fluid is controversial. The choroidal vascular findings as elucidated by recent optical coherence tomography (OCT) and wide-field indocyanine green (ICG) angiographic evaluation show eyes with CSC have many of the same venous patterns that are found in eyes foll...
#1Rebecca Kaye (University of Southampton)H-Index: 6
#2Shruti ChandraH-Index: 4
Last. Andrew J. Lotery (University of Southampton)H-Index: 65
view all 6 authors...
Abstract Central serous chorioretinopathy (CSC) is a common form of vision loss, typically seen in working-age men. The pathophysiology behind CSC still eludes us, however significant advances have been made in understanding this disease over the last decade using information from genetic and cell-based studies and imaging modalities. This review aims to give an overview of the current pathophysiology hypotheses surrounding CSC in addition to future directions in cellular work from human induced...
7 CitationsSource